AmyriAD’s Alzheimer’s drug ready for Phase 3 trials January 11, 2023 AmyriAD CEO tempers expectations on lecanemab and explains how layering therapies may help “turn the clock back” further for Alzheimer’s patients. While much of the limelight at the recent Clinical Trials on Alzheimer’s Disease (CTAD) conference was focused on the data from Eisai and…
AmyriAD Therapeutics CEO Sharon L. Rogers shares the scoop on AmyriAD’s investigational Alzheimer’s drug AD101. December 12, 2022 The majority of experimental Alzheimer’s drugs are being designed to halt the progression of the disease — a strategy which so far has yielded a 99-percent failure rate. Trials for these drugs — mostly expensive antibody-infusion based therapies —…
Los Angeles, CA, November 29, 2022 – AmyriAD Therapeutics (AmyriAD) a privately held, late clinical-stage pharmaceutical development company focused on advancing therapies for Alzheimer’s disease (AD), today announced that it will present data on their lead candidate AD101 at the 15th Clinical Trials on Alzheimer’s Disease Conference (CTAD) on November 29 – December 2 in…
Sharon Rogers of AMYRIAD Therapeutics Discusses the State of Treatments & Trials
Interview with AmyriAD CEO Sharon L. Rogers
Drug developer targets neurotransmission to improve symptoms in AD
Experts Extol Combination Therapies as Future of Alzheimer’s Treatment
Are we Closer to Symptom Management or a Cure for Alzheimer’s?
